Shattuck Labs (STTK) Current Assets (2019 - 2026)
Shattuck Labs (STTK) posted quarterly Current Assets of $93.8 million for Q1 2026, up 41.19% year-over-year from $66.4 million in Q1 2025, and up 13.67% quarter-over-quarter from $82.5 million in Q4 2025.
Shattuck Labs (STTK) Current Assets (2019 - 2026) Analysis & Trends
Shattuck Labs (STTK) has reported Current Assets for 8 consecutive years, with $93.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Assets rose 41.19% year-over-year to $93.8 million; the TTM figure through Mar 2026 stood at $93.8 million (up 41.19% YoY), while the FY2025 annual figure was $82.5 million, up 4.12% from the prior year.
- Current Assets grew to $93.8 million in Q1 2026 per STTK's latest filing, from $82.5 million in the prior quarter.
- Across five years, Current Assets topped out at $255.0 million in Q1 2022 and bottomed at $54.7 million in Q2 2025.
- Historically, Current Assets has averaged $131.3 million across 5 years, with a median of $114.4 million in 2024.
- Annual changes were most pronounced in 2025 — Current Assets sank 52.22% — and 2026, when it jumped 41.19%.
- Shattuck Labs' Current Assets stood at $184.6 million in 2022, then slipped by 22.41% to $143.2 million in 2023, then plunged by 44.69% to $79.2 million in 2024, then climbed by 4.12% to $82.5 million in 2025, then increased by 13.67% to $93.8 million in 2026.
- Business Quant data shows STTK's Current Assets at $93.8 million in Q1 2026, $82.5 million in Q4 2025, and $90.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Shattuck Labs | 962.96 Mn | 962.96 Mn | - | 213.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 213.27 Mn |
| Mar 31, 2026 | 93.75 Mn |
| Dec 31, 2025 | 82.48 Mn |
| Sep 30, 2025 | 90.72 Mn |
| Jun 30, 2025 | 54.68 Mn |
| Mar 31, 2025 | 66.40 Mn |
| Dec 31, 2024 | 79.22 Mn |
| Sep 30, 2024 | 98.74 Mn |
| Jun 30, 2024 | 114.43 Mn |
| Mar 31, 2024 | 131.08 Mn |
| Dec 31, 2023 | 143.22 Mn |
| Sep 30, 2023 | 112.99 Mn |
| Jun 30, 2023 | 136.45 Mn |
| Mar 31, 2023 | 157.84 Mn |
| Dec 31, 2022 | 184.58 Mn |
| Sep 30, 2022 | 201.52 Mn |
| Jun 30, 2022 | 229.42 Mn |
| Mar 31, 2022 | 254.99 Mn |
| Dec 31, 2021 | 288.27 Mn |
| Sep 30, 2021 | 301.64 Mn |